EA033110B1 - Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы - Google Patents

Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы

Info

Publication number
EA033110B1
EA033110B1 EA201491837A EA201491837A EA033110B1 EA 033110 B1 EA033110 B1 EA 033110B1 EA 201491837 A EA201491837 A EA 201491837A EA 201491837 A EA201491837 A EA 201491837A EA 033110 B1 EA033110 B1 EA 033110B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
nucleic acid
expression vector
antigen receptor
chimeric antigen
Prior art date
Application number
EA201491837A
Other languages
English (en)
Other versions
EA201491837A1 (ru
Inventor
Джеймс Нобл Кохендерфер
Original Assignee
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033110(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез filed Critical Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Publication of EA201491837A1 publication Critical patent/EA201491837A1/ru
Publication of EA033110B1 publication Critical patent/EA033110B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

Изобретение относится к выделенной последовательности нуклеиновой кислоты, кодирующей химерный рецептор антигена, который направлен против антигена созревания B-клеток (BCMA), к содержащему указанную последовательность экспрессионному вектору и содержащей указанный вектор выделенной клетке-хозяину, способам ее получения, а также к самому химерному рецептору антигена. Кроме того, предложено применение перечисленных изобретений при получении лекарственных средств для разрушения раковых клеток и их использование в способах разрушения раковых клеток.
EA201491837A 2012-04-11 2013-03-15 Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы EA033110B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261622600P 2012-04-11 2012-04-11
PCT/US2013/032029 WO2013154760A1 (en) 2012-04-11 2013-03-15 Chimeric antigen receptors targeting b-cell maturation antigen

Publications (2)

Publication Number Publication Date
EA201491837A1 EA201491837A1 (ru) 2015-03-31
EA033110B1 true EA033110B1 (ru) 2019-08-30

Family

ID=48045750

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990959A EA201990959A1 (ru) 2012-04-11 2013-03-15 Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
EA201491837A EA033110B1 (ru) 2012-04-11 2013-03-15 Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990959A EA201990959A1 (ru) 2012-04-11 2013-03-15 Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток

Country Status (17)

Country Link
US (19) US9765342B2 (ru)
EP (2) EP3689383A1 (ru)
JP (5) JP6359520B2 (ru)
KR (4) KR102086874B1 (ru)
CN (3) CN104379179A (ru)
AU (4) AU2013246443B2 (ru)
BR (1) BR112014024893B8 (ru)
CA (1) CA2869562C (ru)
EA (2) EA201990959A1 (ru)
HK (1) HK1203393A1 (ru)
IL (4) IL234870B (ru)
IS (1) IS9056A (ru)
MX (3) MX2018008352A (ru)
NZ (1) NZ700362A (ru)
RU (2) RU2650805C2 (ru)
SG (1) SG11201406414WA (ru)
WO (1) WO2013154760A1 (ru)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2014186469A2 (en) 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
WO2015123527A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
ES2737690T3 (es) 2014-02-27 2020-01-15 Ucl Business Ltd Variantes de APRIL
HUE045480T2 (hu) 2014-03-19 2019-12-30 Cellectis CD123-specifikus kiméra antigénreceptorok rák immunoterápiához
US20170029774A1 (en) 2014-04-10 2017-02-02 Seattle Children's Hospital (dba Seattle Children' Research Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
HRP20211910T1 (hr) 2014-04-25 2022-03-18 2Seventy Bio, Inc. Mnd promotor himerni antigen receptori
MX370018B (es) * 2014-04-25 2019-11-28 Bluebird Bio Inc Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
MX2016015834A (es) * 2014-06-02 2017-07-19 Us Health Receptores quiméricos de antigeno que tienen como diana a cd-19.
KR102485855B1 (ko) * 2014-06-06 2023-01-09 2세븐티 바이오, 인코포레이티드 개선된 t 세포 조성물
ES2813437T3 (es) * 2014-07-11 2021-03-23 Celgene Corp Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
EP3172237A2 (en) * 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3172231B1 (en) * 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
CN106922148B (zh) * 2014-07-29 2021-10-15 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
MY191537A (en) * 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CN107206076B (zh) 2014-12-05 2021-07-09 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
ES2750725T3 (es) 2014-12-12 2020-03-26 Bluebird Bio Inc Receptores de antígeno quiméricos BCMA
KR20170090506A (ko) * 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
HUE046054T2 (hu) 2014-12-24 2020-01-28 Aadigen Llc Peptidek és nanorészecskék molekulák intracelluláris célba juttatásához
CN107438618A (zh) * 2015-01-26 2017-12-05 塞勒克提斯公司 赋予结合至cd123的嵌合抗原受体用于治疗复发性/难治性急性骨髓性淋巴瘤或母细胞性浆细胞样树突状细胞肿瘤的t细胞受体敲除的工程化免疫细胞
CN107614008A (zh) * 2015-03-20 2018-01-19 蓝鸟生物公司 载体制剂
AU2016243124A1 (en) 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
KR102528825B1 (ko) 2015-04-13 2023-05-08 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
ES2905315T3 (es) 2015-04-13 2022-04-07 Pfizer Anticuerpos terapéuticos y sus usos
EP3288638A1 (en) 2015-04-25 2018-03-07 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
JP6857141B2 (ja) 2015-05-20 2021-04-14 ノバルティス アーゲー エベロリムスとダクトリシブとの薬学的組合せ
WO2016197064A1 (en) * 2015-06-04 2016-12-08 Epstein Alan L Lym-1 and lym-2 targeted car cell immunotherapy
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CN108026151B (zh) 2015-06-19 2022-07-15 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
KR20180042271A (ko) 2015-08-03 2018-04-25 잉맵 에스에이알엘 Bcma에 대응하는 단일클론 항체
JP7162530B2 (ja) 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11478555B2 (en) 2015-08-17 2022-10-25 Seoul National University R&Db Foundation Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof
MX2018003308A (es) 2015-09-18 2018-11-09 The General Hospital Corp Dba Massacsetts General Hospital Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
WO2017064222A1 (en) 2015-10-16 2017-04-20 Ludwig-Maximilians-Universität München Cxcr6-transduced t cells for targeted tumor therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
US10925969B2 (en) 2015-11-13 2021-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-BCMA polypeptides and proteins
US20190153049A1 (en) * 2015-11-26 2019-05-23 Guangzhou Cas Lamvac Biotech Co., Ltd. Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
CN116121281A (zh) 2015-11-27 2023-05-16 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
CN109641008B (zh) 2016-04-01 2021-03-23 凯德药业股份有限公司 嵌合受体及其方法和用途
AR108427A1 (es) 2016-04-01 2018-08-22 Kite Pharma Inc Antígeno quimérico y receptores de células t y métodos de uso
KR102522622B1 (ko) 2016-04-01 2023-04-18 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
EP3464366A1 (en) 2016-05-27 2019-04-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
AU2017291262A1 (en) 2016-06-30 2019-01-03 F. Hoffmann-La Roche Ag Improved adoptive T-cell therapy
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CA3036972A1 (en) * 2016-09-14 2018-03-22 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
PL3445787T3 (pl) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CA3041183A1 (en) 2016-11-02 2018-05-11 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
MX2019006090A (es) 2016-11-23 2019-08-21 Novartis Ag Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
WO2018102752A1 (en) * 2016-12-02 2018-06-07 Cartesian Therapeutics, Inc. Cancer immuno therapy with highly enriched cd8+ chimeric antigen receptor t cells
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
WO2018128485A1 (ko) * 2017-01-05 2018-07-12 한국생명공학연구원 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
MX2019011324A (es) 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
JP2020511987A (ja) * 2017-03-28 2020-04-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 移植された組織を拒絶反応から保護するための方法
WO2018183842A1 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
BR112019022893A2 (pt) 2017-05-01 2020-05-19 Juno Therapeutics Inc combinação de uma terapia celular e um composto imunomodulatório
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11622977B2 (en) 2017-05-12 2023-04-11 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
ES2928296T3 (es) * 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
WO2019025983A1 (en) 2017-08-01 2019-02-07 Medimmune, Llc CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA
US20200255526A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN111107874A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CA3075714A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200116077A (ko) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CN109748968B (zh) * 2017-11-03 2020-12-01 西安宇繁生物科技有限责任公司 Bcma特异性嵌合抗原受体t细胞及其应用
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2020006689A (es) * 2017-12-20 2020-11-06 Poseida Therapeutics Inc Composiciones de vcar y metodos de uso.
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019149250A1 (zh) * 2018-02-01 2019-08-08 南京驯鹿医疗技术有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
AU2019214163B2 (en) * 2018-02-01 2021-06-24 Innovent Biologics (Suzhou) Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
CN111868246A (zh) 2018-02-09 2020-10-30 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110157675B (zh) * 2018-02-12 2022-05-27 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
CN112262212A (zh) 2018-04-24 2021-01-22 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
KR20210008502A (ko) 2018-05-11 2021-01-22 크리스퍼 테라퓨틱스 아게 암을 치료하기 위한 방법 및 조성물
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
BR112020025048A2 (pt) 2018-06-13 2021-04-06 Novartis Ag Receptores de antígeno quimérico de bcma e usos dos mesmos
JP2021534783A (ja) 2018-08-31 2021-12-16 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
BR112021004383A2 (pt) 2018-09-28 2021-08-03 Massachusetts Institute Of Technology proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020089794A1 (en) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2020092854A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CA3177829A1 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
SG11202009283QA (en) 2019-01-16 2020-10-29 Caribou Biosciences Inc Humanized bcma antibody and bcma-car-t cells
SG11202108655TA (en) 2019-02-15 2021-09-29 Univ Southern California Lym-1 and lym-2 antibody compositions and improved car constructs
SG11202107825WA (en) 2019-02-25 2021-09-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
MX2021010288A (es) 2019-03-01 2021-09-23 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
CA3128971A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
KR102588292B1 (ko) 2019-03-15 2023-10-11 카티전 테라퓨틱스, 인코포레이티드 항-bcma 키메라 항원 수용체
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020200303A1 (zh) 2019-04-04 2020-10-08 上海医药集团股份有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
WO2020222176A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3967329A4 (en) 2019-05-07 2023-06-14 Gracell Biotechnologies (Shanghai) Co., Ltd. AGAINST BCMA GM IMMUNE CELLS AND THEIR USE
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
US20220251228A1 (en) 2019-07-30 2022-08-11 Shanghai Hansoh Biomedical Co., Ltd. Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof
MX2022001626A (es) 2019-08-06 2022-03-02 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y procedimientos conexos.
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20210047423A1 (en) 2019-08-16 2021-02-18 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN112409482B (zh) * 2019-08-20 2022-08-26 杭州尚健生物技术有限公司 Bcma抗体
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US20220370500A1 (en) * 2019-09-18 2022-11-24 Board Of Regents, The University Of Texas System A method of engineering natural killer-cells to target bcma-positive tumors
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN110642953B (zh) * 2019-10-12 2021-09-17 华夏源（上海）细胞基因工程股份有限公司 一种靶向bcma的t细胞受体融合蛋白和应用
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
MX2022006391A (es) 2019-11-26 2022-06-24 Novartis Ag Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
CA3164666A1 (en) * 2020-01-13 2021-07-22 Kanya Lakshmi RAJANGAM Bcma-directed cellular immunotherapy compositions and methods
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20220166282A (ko) 2020-03-10 2022-12-16 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
EP4118112A1 (en) 2020-03-10 2023-01-18 Massachusetts Institute of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
WO2021222330A2 (en) 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
KR102400977B1 (ko) 2020-05-29 2022-05-25 성균관대학교산학협력단 프로세서를 통한 페이지 폴트 처리 방법
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2022035793A1 (en) * 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
AU2021341969A1 (en) 2020-09-08 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
EP4226972A1 (en) 2020-10-12 2023-08-16 Nanjing Iaso Biotechnology Co., Ltd. Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof
EP4238990A1 (en) 2020-11-01 2023-09-06 Nanjing Iaso Biotechnology Co., Ltd. Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
EP4257617A1 (en) 2020-12-01 2023-10-11 Cure Genetics Co., Ltd Antigen-binding protein targeting cd70 and use thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
EP4279508A1 (en) 2021-01-12 2023-11-22 Nanjing Iaso Biotechnology Co., Ltd. Cd5-targeting fully humanized antibody
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
EP4322959A2 (en) 2021-04-16 2024-02-21 Celgene Corporation Combination therapies with bcma-directed t cell therapy
WO2022221737A1 (en) 2021-04-16 2022-10-20 Juno Therapeutics, Inc. T cell therapy in patients who have had prior stem cell transplant
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
TW202323822A (zh) 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 生藥組合物及穩定同位素標記肽之圖譜定位方法
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
AU2022330406A1 (en) 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
WO2023025208A1 (zh) 2021-08-24 2023-03-02 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
WO2023025207A1 (zh) 2021-08-24 2023-03-02 赛斯尔擎生物技术（上海）有限公司 T细胞产品及其用途
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
CN114015674A (zh) 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 新型CRISPR-Cas12i系统
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
US20230136301A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
AR128124A1 (es) 2021-12-30 2024-03-27 Tr1X Inc Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
WO2011041093A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012031744A1 (en) * 2010-09-08 2012-03-15 Chemotherapeutisches Forschungsinstitut Chimeric antigen receptors with an optimized hinge region

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IN165717B (ru) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU2005200008B2 (en) * 1999-01-07 2008-03-06 Zymogenetics, Inc. Soluble receptor BR43x2 and methods of using
GB0013345D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Modified receptor and assay
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
JP3934673B1 (ja) * 2003-06-18 2007-06-20 ジェネラックス・コーポレイション 修飾組換えワクシニアウイルスおよびその他の微生物、その使用
SI1776383T1 (sl) 2004-07-22 2014-12-31 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
RU2007142523A (ru) * 2005-05-18 2009-06-27 БИОГЕН ИДЕК Инк. (US) Способы лечения фиброзных состояний
US8603950B2 (en) 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
DK2265283T3 (da) * 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
RU2444570C1 (ru) * 2010-06-23 2012-03-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения и социального развития Российской Федерации Способ получения рекомбинантной вакцины
US9487800B2 (en) 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
SG10201510092QA (en) * 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL3415531T3 (pl) 2011-05-27 2024-02-26 Glaxo Group Limited Białka wiążące antygen
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
IN2014DN07414A (ru) 2012-02-22 2015-04-24 Univ Pennsylvania
EA201990959A1 (ru) * 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US10925969B2 (en) * 2015-11-13 2021-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-BCMA polypeptides and proteins
CA3096798A1 (en) * 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
ES2928296T3 (es) 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
WO2011041093A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012031744A1 (en) * 2010-09-08 2012-03-15 Chemotherapeutisches Forschungsinstitut Chimeric antigen receptors with an optimized hinge region

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOCHENDERFER J N; FELDMAN S A; ZHAO Y; XU H; BLACK M A; MORGAN R A; WILSON W H; ROSENBERG S A: "Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 32, no. 7, 1 September 2009 (2009-09-01), US, pages 689 - 702, XP009133189, ISSN: 1524-9557 *
KOCHENDERFER JAMES N; DUDLEY MARK E; STETLER-STEVENSON MARYALICE; WILSON WYNDHAM H; JANIK JOHN E; NATHAN DEBBIE-ANN N; MARIC IRINA: "A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 21, 1 November 2010 (2010-11-01), US, pages 1179 - 1180, XP009170179, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
RU2766608C2 (ru) 2022-03-15
WO2013154760A1 (en) 2013-10-17
AU2013246443A1 (en) 2014-10-23
JP6989634B2 (ja) 2022-01-05
US10829768B2 (en) 2020-11-10
BR112014024893B1 (pt) 2021-03-30
BR112014024893B8 (pt) 2022-09-06
AU2013246443B2 (en) 2017-04-27
US20200102567A1 (en) 2020-04-02
MX2014012222A (es) 2014-11-25
JP6657317B2 (ja) 2020-03-04
BR112014024893A2 (pt) 2017-07-11
KR20150003306A (ko) 2015-01-08
CN110295186A (zh) 2019-10-01
AU2019203042B2 (en) 2021-03-11
NZ700362A (en) 2016-09-30
US11773396B2 (en) 2023-10-03
US20200071706A1 (en) 2020-03-05
IL278003A (en) 2020-11-30
AU2021202158A1 (en) 2021-05-06
HK1203393A1 (en) 2015-10-30
KR20200027047A (ko) 2020-03-11
US10767184B2 (en) 2020-09-08
IL263417A (en) 2018-12-31
US20210095294A1 (en) 2021-04-01
US10815487B2 (en) 2020-10-27
IL263417B (en) 2020-10-29
MX357823B (es) 2018-07-25
US20200071707A1 (en) 2020-03-05
US20200087670A1 (en) 2020-03-19
AU2019203042A1 (en) 2019-05-23
IS9056A (is) 2014-10-06
US20200071710A1 (en) 2020-03-05
US10844387B2 (en) 2020-11-24
IL290471A (en) 2022-04-01
US20230002776A1 (en) 2023-01-05
US20230030998A1 (en) 2023-02-02
SG11201406414WA (en) 2014-11-27
US20200087667A1 (en) 2020-03-19
US10900042B2 (en) 2021-01-26
US20200071705A1 (en) 2020-03-05
MX2022009653A (es) 2022-09-07
JP2022058345A (ja) 2022-04-12
US10837019B2 (en) 2020-11-17
KR20220029757A (ko) 2022-03-08
CN110331154A (zh) 2019-10-15
JP6359520B2 (ja) 2018-07-18
US20200087668A1 (en) 2020-03-19
IL234870A0 (en) 2014-12-31
US11066674B2 (en) 2021-07-20
JP2018161140A (ja) 2018-10-18
RU2018111462A (ru) 2019-02-27
US20200087669A1 (en) 2020-03-19
KR102086874B1 (ko) 2020-03-10
US20200071709A1 (en) 2020-03-05
US9765342B2 (en) 2017-09-19
JP2015513920A (ja) 2015-05-18
AU2017208279A1 (en) 2017-08-10
EP2836239A1 (en) 2015-02-18
JP2023175763A (ja) 2023-12-12
EA201990959A1 (ru) 2020-02-10
US20200071708A1 (en) 2020-03-05
CA2869562C (en) 2023-09-12
US10876123B2 (en) 2020-12-29
IL234870B (en) 2020-06-30
EA201491837A1 (ru) 2015-03-31
CA2869562A1 (en) 2013-10-17
RU2650805C2 (ru) 2018-04-17
US20150051266A1 (en) 2015-02-19
US20180051292A1 (en) 2018-02-22
AU2017208279B2 (en) 2019-03-07
EP3689383A1 (en) 2020-08-05
CN104379179A (zh) 2015-02-25
US10829767B2 (en) 2020-11-10
US10829769B2 (en) 2020-11-10
KR20210032014A (ko) 2021-03-23
US11827889B2 (en) 2023-11-28
US20230050416A1 (en) 2023-02-16
US11359204B2 (en) 2022-06-14
MX2018008352A (es) 2022-08-10
KR102229945B1 (ko) 2021-03-18
US10815488B2 (en) 2020-10-27
US11377660B2 (en) 2022-07-05
JP2020078322A (ja) 2020-05-28
US20210095295A1 (en) 2021-04-01
US20210123063A1 (en) 2021-04-29
RU2014144143A (ru) 2016-06-10
US10738313B2 (en) 2020-08-11
RU2018111462A3 (ru) 2021-07-27
US10738312B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
EA033110B1 (ru) Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
TN2014000438A1 (en) Anti-fcrn antibodies
MX2015014423A (es) Administración efectiva de genes grandes por vectores aav duales.
MX353621B (es) Variantes de alfa-amilasa.
MX2013007997A (es) Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
WO2014116846A3 (en) Methods and compositions for modulating an immune response
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX2012011774A (es) Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que codifican los mismos.
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP4219536A3 (en) Targeted/immunomodulatory fusion proteins and methods for making same
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2013007853A (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
IN2014CN04586A (ru)
GB201106750D0 (en) Novel compounds
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
MX2013004892A (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
MX2015013447A (es) Polipeptidos que tienen actividad de la fosfolipasa a y polinucleotidos que los codifican.
PH12016500753B1 (en) Antibodies specific to fcrn
MX350713B (es) Variantes de subtilisina y polinucleotidos que las codifican.
MX2014015766A (es) Receptores de tipo toll y oligonucleotidos inmunoestimuladores.